Alkem Laboratories Ltd Share Price Today - Alkem Laboratories Ltd Stock Price Live NSE/BSE

Alkem Laboratories Ltd

NSE: ALKEM BSE: 539523

₹5257.50

(0.33%)

Mon, 30 Mar 2026, 00:13 am

MTF 5xInvest in Alkem Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap628.64B

PE Ratio26.54

Dividend0.97

Health Technology

Pharmaceuticals: Major

24.5K

Alkem Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
63889.56
Net Profit
2216
P/B
4.87
Sector P/E
31.93
P/E
26.94
EV/EBITDA
19.35
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
19.88
ROCE
20.03
Debt/Equity
0.13
EPS (TTM)
200.85
Dividend Yield
0.84
Book Value
1116.21
Interest Cover
21.76

Analysis

all

Pros

Dividends paid are well covered by earnings (3.8x coverage).
Dividends after 3 years are expected to be well covered by earnings (4.7x coverage).
Alkem Laboratories's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
Cash flow for Alkem Laboratories is expected to increase by more than 50% in 2 years time.
Alkem Laboratories's earnings growth is expected to exceed the low risk savings rate of 7.2%.

Cons

Dividend payments have increased, but Alkem Laboratories only paid a dividend in the past 4 years.
Alkem Laboratories has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
Alkem Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
Alkem Laboratories's earnings are expected to grow by 13.5% yearly, however this is not considered high growth (20% yearly).
Alkem Laboratories's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	51.20	51.20	53.04	55.13	55.66
FII	9.97	9.48	9.11	9.41	10.15
DII	21.54	21.93	21.80	19.42	18.01
Public	17.30	17.40	16.05	16.05	16.18
Government	0	0	0	0.00	0.00

Technical Analysis

RSI

45.83

MACD

-75.43

50 DMA

5562.29

200 DMA

5401.53

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	6800.67	6214.17	5926.83	5627.67	5340.33	5041.17	4454.67
Fibonacci	6214.17	5990.12	5851.71	5627.67	5403.62	5265.21	5041.17
Camarilla	5800.79	5747.02	5693.26	5627.67	5585.74	5531.98	5478.21

Pivots Level: Classic

+1173

6800.67

+586.50

6214.17

+299.17

5926.83

5627.67

Pivot Point

LTP: 5344.50

-287.33

5340.33

-586.50

5041.17

-1173

4454.67

Moving Average

SMAEMA

Period

Value

10-EMA
5342.76
20-EMA
5400.06
30-EMA
5446.17
50-EMA
5501.26
100-EMA
5521.93
200-EMA
5452.29

Announcement Date	Purpose	Action	Ex Date
13 Feb 2026	board-meetings	Quarterly Results, Interim Dividend
13 Feb 2026	dividend	₹43.00 Dividend /Share	20 Feb 2026
13 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
08 Jul 2025	dividend	Final Dividend - Rs. - 8	08 Aug 2025
29 May 2025	agm
29 May 2025	dividend	₹8.00 Dividend /Share	08 Aug 2025
07 Feb 2025	dividend	₹37.00 Dividend /Share	14 Feb 2025
14 Jan 2025	dividend	Interim Dividend - Rs. - 37	14 Feb 2025
10 Jul 2024	dividend	Final Dividend - Rs. - 5	10 Aug 2024
09 Jul 2024	dividend	Dividend - Rs 5 Per Share	10 Aug 2024

Alkem Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd

Lupin Ltd

Alkem Laboratories Ltd About

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1973

Headquarters

CEO

Basudeo N Singh

Employees

Contact

Website

http://www.alkemlabs.com

investors@alkem.com ; contact@alkem.com

Phone

91-22-39829999

Location

Alkem House SenapatiBapat Marg, Lower Parel, Mumbai, Maharashtra, 400013

Year	History
2019	Alkem crossed the revenue milestone of USD 1 billion. Alkem received the Express Pharma Excellence Award at Pharma CXO Summit 2019. Alkem Laboratories took over an undertaking from Cachet Pharmaceuticals.
2020	Alkem launched Favipiravir in India under the brand name 'Alfluenza'. Alkem received the 'Best IT team of the Year' award at the CIO Conclave and Awards 2020.
2021	Alkem launched Ibuprofen and Famotidine Tablets in the United States. Alkem launched Perampanel Tablets in India under the brand name 'Perampil'. Alkem launched Brivaracetam in India under the brand name 'Brivasure'. Alkem partnered with Tata Memorial Hospital. Alkem was recognized as one of India's Best Workplaces in Biotechnology & Pharmaceutical Industry for the second consecutive year.
2022	Alkem signed a license agreement with Harvard University's Office of Technology Development.
2023	The Company entered into a co-development and license agreement with Biosergen AB for the development and commercialization of BSG005. The NCLT approved the Scheme of Amalgamation for the merger of Pharmasofttech Awacs Pvt. Ltd. into Pharmarack Technologies Pvt. Ltd.

Client Name	Order Side	QTY	Avg Price	Date
SAMPRADA&NANHAMATI SINGH FAMILY TRUST	Sell	755400	4831.92	11 Jun 2025
JAYANTI SINHA	Sell	1700000	4874.61	04 Jun 2025
SAMPRADA&NANHAMATI SINGH FAMILY TRUST	Sell	641712	4680	21 Feb 2025
UBS PRINCIPAL CAPITAL ASIA LIMITED	Sell	989506	5468.99	25 Nov 2024
SAMPRADA&NANHAMATI SINGH FAMILY TRUST	Sell	850000	5732.15	22 Aug 2024
RAJEEV RANJAN	Sell	1000000	4950	18 Jun 2024
RAJESH KUMAR	Sell	1000000	4950.22	18 Jun 2024
PRASID UNO FAMILY TRUST	Sell	3660000	1708.45	22 Aug 2019
ADITYA BIRLA SUN LIFE MUTUAL FUND	Buy	750000	1708.45	22 Aug 2019
SBI MUTUAL FUND	Buy	2400000	1708.45	22 Aug 2019

Alkem Laboratories Ltd News

Alkem Labs Appoints Samsheer Kumar Deo to Senior Role

Alkem Laboratories announces the appointment of Mr. Samsheer Kumar Deo to a senior management position effective March 27th, 2026, bringing 29 years of sales experience to strengthen company performance.

27 Mar 2026

companies

Alkem Labs Gets EU GMP Certificate for Daman Facility

Alkem Laboratories receives Certificate of GMP Compliance from Malta Medicines Authority for its Daman manufacturing facility, valid for 3 years from December 9, 2025.

23 Mar 2026

companies

Alkem Labs Launches Semaglutide at INR 450/Week

Alkem Laboratories launches semaglutide injection in India under three brand names with DCGI approval for diabetes and weight management at INR 450 weekly cost.

21 Mar 2026

companies

Alkem Labs Launches Affordable Semaglutide Injection

Alkem Laboratories introduces semaglutide injection in India at INR 450 per week, making diabetes treatment more accessible to patients across the country.

21 Mar 2026

companies

Alkem Labs Gets EU GMP Certificate for Daman Facility

Alkem Laboratories receives Certificate of GMP Compliance from Malta Medicines Authority for its Daman manufacturing facility, valid for 3 years from December 9, 2025.

20 Mar 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800